If a single peptide could give you the metabolic signature of an endurance athlete without changing into lycra, it would be one of the most disruptive molecules in modern wellness. SLU-PP-332, a synthetic agonist of the oestrogen-related receptors ERRα, ERRβ, and ERRγ, was first described in a 2023 paper in Cell by Goncalves et al. from the Scripps Research Institute as a bona fide "exercise mimetic" — a compound that, in obese mice and primary human skeletal muscle myotubes, activates the same genetic programme as a treadmill regimen, without any treadmill.
For the South African wellness audience, the relevance is direct. The BioMuti SLU-PP-332 2mg vial is positioned as an "exercise in a bottle" for clients whose training capacity is limited by joint pain, time scarcity, chronic fatigue, or recovery from illness. To understand whether that positioning is science or marketing, it helps to walk through the molecular logic, the rodent evidence, the human-cell data, and the boundaries that still apply in 2026.
The ERR family and the endurance genetic programme
ERRα, ERRβ, and ERRγ are orphan nuclear receptors that bind to oestrogen response elements on DNA but are activated by metabolic cues rather than oestrogen itself. ERRα in particular is the master regulator of mitochondrial biogenesis in oxidative tissues — heart, slow-twitch skeletal muscle, kidney, and brown adipose. When ERRα is activated, downstream programmes switch on that mirror exactly what happens during chronic endurance training:
- Increased mitochondrial density per muscle fibre
- Shift from glycolytic (fast-twitch) to oxidative (slow-twitch) fibre phenotype
- Upregulated fatty acid oxidation and ketolytic enzymes
- Improved running endurance and VO₂max in animal models
- Resistance to diet-induced obesity and fatty liver
The seminal Scripps work is summarised on PubMed Central and showed that oral SLU-PP-332 in sedentary, obese mice produced an endurance gain equivalent to a 6-week treadmill regimen, while reducing fasting glucose, hepatic steatosis, and adiposity — all without changing food intake.
What the 2025 and 2026 follow-up literature added
The original Scripps paper kicked off a wave of follow-up. A 2025 study indexed at PubMed extended the work to cardiac tissue, showing that ERR agonism protects against pressure-overload heart failure via improved mitochondrial quality control in cardiomyocytes. A separate 2025 publication in Nature Metabolism demonstrated that SLU-PP-332 increases whole-body energy expenditure in non-human primates — a meaningful step up the translational ladder from mouse to primate, though still short of human Phase II data.
For longevity researchers, the most interesting result is the overlap with the NAD⁺/sirtuin axis. Studies on PubMed Central show that SIRT3 deacetylase activity, ERRα transcriptional output, and mitochondrial uncoupling proteins are co-regulated, which is why an ERR agonist has knock-on effects on insulin sensitivity, hepatic lipid handling, and oxidative-stress defence — the same triad implicated in NAD⁺ precursor research. BioMuti's broader longevity stack — NAD+ 1000mcg, SLU-PP-332 2mg, and the Glow Stack — is built around exactly this overlap.
Why the peptide is described as "not a stimulant"
Walk past any pharmacy in Johannesburg or Cape Town and you'll see nootropic and "fat-burner" products that lean on caffeine, synephrine, or yohimbine. SLU-PP-332 sits in a fundamentally different category. It does not raise heart rate acutely, does not deplete catecholamines, and does not produce the jittery wakefulness associated with sympathomimetic stimulants. Its action is transcriptional: it changes which genes your muscle cells are reading, not how hard your adrenal glands are firing.
That distinction matters because the "energy expenditure" the compound generates is distributed across the day rather than delivered as a single acute pulse. ClinicalTrials.gov currently lists early-stage trials exploring ERR agonists in heart failure with preserved ejection fraction (HFpEF) and in age-related sarcopenia, and the metabolic outcomes being measured are exactly the chronic, distributed kind — VO₂max, lean mass, hepatic fat fraction — not acute spikes in cortisol or adrenaline.
Limits and open questions
Three caveats are worth flagging before anyone interprets "exercise in a bottle" too literally.
1. No replacement for muscle contraction. SLU-PP-332 cannot strengthen bone density, maintain tendon health, or preserve neuromuscular coordination. Resistance training confers benefits the molecule does not. The honest framing is "metabolic mimicry", not "training replacement".
2. Human pharmacokinetics are still sparse. Most published work is in rodents and primates. Oral bioavailability in humans, optimal dosing window, and long-term safety profile are still being established.
3. Stacking effects are unstudied. SLU-PP-332 stacked with Tesamorelin, Ipamorelin, or MOTS-c is biologically plausible because the targets are complementary, but peer-reviewed data on these specific combinations is not yet available.
Where SLU-PP-332 sits in a BioMuti protocol
For most South African clients, the realistic use case is layering, not substitution. A reasonable protocol pairs the peptide with reduced-intensity steady-state cardio (zone 2), adequate protein, and sleep prioritisation — all of which are independently supported by the mitochondrial research literature. The peptide amplifies the signal the training sends; the training still has to happen for the bone, tendon, and cognitive dividends.
For clients recovering from injury, post-illness deconditioning, or age-related sarcopenia, the peptide can act as a bridge — preserving the metabolic phenotype until training volume is rebuilt. For high-performing athletes, it can extend the endurance ceiling by raising the baseline oxidative capacity between training blocks. Either way, the science says: signalling, not substitution.
SLU-PP-332 is one of the more intellectually interesting peptides to enter the wellness conversation in recent years, not because it replaces hard work, but because it reveals how much of "hard work" is actually a transcriptional pattern that the body can be nudged into pharmacologically. That distinction will define the next decade of performance medicine.
